$JUBLINGREA

Jubilant Ingrevia shares declined despite the company reporting a strong set of Q1 FY27 results, reflecting cautious investor sentiment after the recent rally in the stock. The specialty chemicals company posted a 41 percent year on year increase in consolidated net profit to Rs 106 crore, while revenue from operations rose 25.3 percent to Rs 1,300.3 crore. EBITDA also grew 40 percent to Rs 199.1 crore, with the EBITDA margin improving to 15.3 percent from 13.7 percent a year ago. Following the earnings announcement, brokerage Anand Rathi reiterated its Buy rating on the stock and raised its target price to Rs 980, implying an upside of around 34 percent from current levels. The brokerage attributed the strong quarterly performance to healthy pricing in the Nutrition and Health Solutions and Chemical Intermediates segments, higher volumes in Specialty Chemicals, and effective cost pass through across key businesses. Management maintained its FY27 EBITDA guidance of Rs 7.5 billion to Rs 8 billion, expecting growth to be driven by higher Agro CDMO dispatches, expansion in Fine Chemicals, and faster ramp up of human grade Vitamin B3 production. While the market reaction remained subdued, analysts believe the company's operational momentum and improving demand environment support its long term growth outlook.